Please wait while we load the requested 10-Q report or click the link below:
Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019
Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated
First topline data from PRECISION-HD clinical program expected by year-end
CAMBRIDGE, Mass., July 29, 2019 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30, 2019 and provided a business update.
Wave continues to make significant progress in advancing its pipeline and I am pleased to report that we are on track to deliver data from our first two clinical programs by the end of the year. First, we expect to share dystrophin biopsy data from the ongoing open-label extension study of investigational suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping, followed by the first clinical data for our differentiated, allele-selective approach to treating Huntingtons disease, said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. For suvodirsen, the recent initiation of our Phase 2/3 DYSTANCE 51 trial marks a significant milestone towards our goal of bringing new therapies to patients living with DMD globally. Lastly, we are leveraging our PRISM platform to advance several exciting preclinical programs in DMD, HD, ALS/FTD, and ophthalmology.
Wave is committed to building a fully integrated genetic medicines company led by its clinical and preclinical programs for the treatment of neuromuscular, central nervous system and ophthalmologic diseases.
First clinical dystrophin data from the suvodirsen open-label extension study for DMD patients amenable to exon 51 skipping are expected in 4Q 2019
Suvodirsen is currently being studied in an open-label extension (OLE) study in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The study was initiated in August 2018 with patients from the Phase 1 clinical trial. Wave is on track to deliver an interim analysis of dystrophin expression from muscle biopsies in boys receiving suvodirsen, which is expected in the fourth quarter of 2019. This interim analysis will include dystrophin expression from muscle biopsies taken 22 weeks after patients enrolled in the OLE were transitioned to one of the Phase 2/3 doses of suvodirsen, as well as a safety summary.
In June at the 2019 Parent Project Muscular Dystrophy (PPMD) Annual Conference, Wave reported an apparent decline in infusion-associated symptoms with continued weekly dosing of suvodirsen in the OLE among the 25 patients (of 37 expected to enroll) dosed at the Phase 2/3 doses as of June 18, 2019. In total, 148 doses had
The following information was filed by Wave Life Sciences Ltd. (WVE) on Monday, July 29, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Wave Life Sciences Ltd.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Wave Life Sciences Ltd..